Cognitive decline is faster in Lewy body variant than in Alzheimer's disease

Neurology

Volumn 51, Issue 2, 1998, Pages 351-357

  Olichney, John M ^c   Galasko, D ^d   Salmon, D P ^a   Hofstetter, C R ^b   Hansen, L A ^a   Katzman, R ^a   Thal, L J ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; COGNITION; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HYPOTHESIS; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROFIBRILLARY TANGLE; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0031722580     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.2.351     Document Type: Article

References (50)

1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
2. McKeith IG, Fairbairn AF, Perry RH, Thompson P. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994;165:324-332.
3. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-895.
4. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
5. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer's disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
6. Hansen LA, Samuel W. Criteria for Alzheimer's disease and its nosology of dementia with Lewy bodies. Neurology 1997;48: 126-132.
7. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
8. Mirra SS, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
9. St. Clair D, Norrman J, Perry R, Yates C, Wilcock G, Brooks A. Apolipoprotein E ∈4 allele frequency in patients with Lewy body dementia, Alzheimer's disease and age-matched controls. Neurosci Lett 1994;176:45-46.
10. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E genotype and Lewy body disease. Neurology 1995;45:97-103.
11. Harrington CR, Louwagie J, Rossau R, et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Am J Pathol 1994;145:1472-1484.
12. McKeith IG, Perry RH, Fairbairn AF, et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911-922.
13. Galasko D, Katzman R, Salmon DP, Hansen L. Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 1996;31:166-175.
14. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 1997;54:969-975.
15. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology 1994;44:2300-2307.
16. Stern Y, Liu X, Albert M, et al. Modelling the influence of extrapyramidal signs on the progression of Alzheimer's disease. Arch Neurol 1996;53:1121-1126.
17. Miller TP, Tinklemberg J, Brooks JE, Yesavage JA. Cognitive decline in patients with and without extrapyramidal signs. Alzheimer Dis Assoc Disord 1991;5:251-256.
18. Armstrong TP, Hansen LA, Salmon DP, et al. Rapidly progressive dementia in a patient with the Lewy body variant of Alzheimer's disease. Neurology 1991;41:1178-1180.
19. Klauber MR, Hofstetter CR, Hill LR, et al. Patterns of decline in the Lewy body variant of Alzheimer's disease. Archives of Psychiatry Shanghai 1992;4(suppl):5053.
20. Ballard C, Patel A, Oyebode F, Wilcock G. Cognitive decline in patients with Alzheimer's disease. Vascular dementia and senile dementia of Lewy body type. Age Ageing 1996;25:209-213.
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed.-Revised. Washington, DC: American Psychiatric Association, 1987.
22. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
24. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease, vol. 2. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
25. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman AL. The Consortium to Establish a Registry for Alzheimer's Disease. Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995;45: 461-466.
26. Katz S, Ford AB, Moskowitz RW, et al. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
27. McKeith IG, Fairbairn AF, Perry RH, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-678.
28. McKeith IG, Fairbairn A, Harrison R. Management of the noncognitive symptoms of Lewy body dementia. In: Perry RH, McKeith IG, Perry EK, eds. Dementia with Lewy bodies. New York, NY: Cambridge University Press, 1996:381-396.
29. Drachman DA, O'Donnell BF, Lew RA, Swearer JM. The prognosis in Alzheimer's disease: 'how far' rather than 'how fast' best predicts the course. Arch Neurol 1990;47:851-856.
30. Nagy Z, Erisi MM, Jobst KA, et al. The effects of additional pathology on the cognitive deficit in Alzheimer's disease. J Neuropathol Exp Neurol 1997;56:165-170.
31. Hughes A, Daniel S, Blankson S, et al. A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50:140-148.
32. Brown R, Marsden C. "Subcortical dementia": the neuropsychological evidence. Neuroscience 1988;25:363-387.
33. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Arch Neurol 1992;49:492-497.
34. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
35. Duyckaerts C, Gaspar P, Costa C, Bonnet AM, Hauw JJ. Dementia in Parkinson's disease: morphometric data. Adv Neurol 1993;60:447-455.
36. de Vos RAI, Jansen ENH, Stam FC, et al. "Lewy body disease: clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 1995;97:13-22.
37. Lennox G, Lowe J, Landon M, et al. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989;52:81-88.
38. Samuel W, Galasko D, Masliah K, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:44-52.
39. Banshor C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett 1993;162:179-182.
40. Samuel W, Alford M, Hofstetter R, Hansen L. Dementia with Lewy bodies versus pure Alzheimer's disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997;56:41-50.
41. Olichney JM, Hansen L, Galasko D, et al. Does the apolipoprotein E ε4 allele accelerate the formation of hippocampal neuritic plaques? Soc Neurosci Abstr 1995;21:1485. Abstract.
42. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993; 43:1927-1934.
43. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer's disease. Alzheimer Dis Assoc Disord 1993;7:69-79.
44. Olichney JM, Galasko D, Corey-Bloom J, Thai LJ. The spectrum of diseases with diffuse Lewy bodies. In: Weiner WJ, Lang AE, eds. Behavioral neurology of movement disorders. Advances in neurology, vol. 65. New York: Raven Press, 1995: 159-170.
45. Schmidt M, Murray J, Lee V-Y, et al. Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991;139:53-65.
46. Alonso AD, Grunde-Iqbal I, Barra HS, Iqbal K. Abnormal phosphorylation of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the dissembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 1997;94:298-303.
47. Feigner H, Frank R, Biernat J, et al. Domains of neuronal microtubule-associated proteins and flexural rigidity of microtubules. J Cell Biol 1997;138:1067-1075.
48. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski J, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature 1997;839-840.
49. Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-Aβ component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 1995;34:10139-10145.
50. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.